Investigational therapies

Overview: There are ongoing studies for treating HCM or its symptoms. These are called investigational therapies. 

In this section we are going to talk about them and their pathway to consumers.  


Investigational therapies under clinical investigation

There are several new therapies under investigation for use in HCM. Below is a list of several medications at different stages of discovery, trial, or submission to the FDA (Food and Drug Administration - USA)


CK-274: This agent is in the same class as Mavacamten, with slight differences in the action.   Clinical trials are ongoing. Sponsor: Cytokinetics

IMB-101 Indication: HCM: Phase 2 study in non-obstructive HCM.  For non-obstructive HCM patients with preserved systolic function (ejection fraction (EF) ≥50%) who develop symptoms refractory to drug therapy, a heart transplant remains the only definitive long-term management option. Sponsor: Imbria Pharmaceuticals

TN-201: This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic MYBPC3 mutation-associated nonobstructive hypertrophic cardiomyopathy (nHCM). Sponsor: Tenaya Therapeutics

HCMA 7/2023